With the Delhi High Court's verdict, Daiichi Sankyo has scored a victory against former Ranbaxy promoters. But it won't end there.

Develoment comes barely a week after the US assured India that the H1-B visas issue was not a priority for it and would be part of the larger immigration reforms package.

Indian drug makers, most of which count the United States as their biggest export market, were the top losers on the key indexes on Friday.

The Sensex fell further after the reports of criminal investigation of generic makers over suspected price collusion and closed  156 points lower.

Market rallied buoyed by manufacturing PMI for September that came in above the 50-mark for the ninth straight month signalling expansion, and improving business conditions.

Sunday night, a bunch of militants opened fire on an Indian army camp in north Kashmir, brewing fresh tensions between India and Pakistan.

The emails and communications in question are stored on Microsoft's servers in Ireland, and contained evidence relating to an ongoing drug and money laundering case in New York.

The energy sector of the S&P was dragged lower by Exxon and Chevron as oil futures prices fell nearly 5 per cent after crude stockpiles fell slightly less than forecast.

The business model to conduct operations, whether it is franchise or management, is immaterial to the risks that could arise around FCPA violation

The lawsuit marks an escalation in the Internet industry's battle over gag orders by the US government on the nature and number of requests for private user information.

The company said it had received a civil investigative demand (CID) from the U.S. Department of Justice (DOJ) and that it would fully cooperate with the investigation.

When I met Srinivasan at his India Cements office in December 2010, he spoke at length about his business and his passion for cricket: his company had traditionally employed some of India's best cricketers. His story is a reminder of the intertwining of politics, patronage, cricket and money.

Fortis Healthcare Executive Chairman Malvinder Singh, while rebutting Japanese firm Daiichi Sankyo's charges, says the company failed in growing the Ranbaxy business.

The pharma major is still to get its Paonta Sahib and Dewas units back on track for inspection and approval by the FDA so that it can resume supplies to the US from these facilities.

Ten days after the US Department of Justice announced that Ranbaxy had pleaded guilty and agreed to pay $500 million as settlement for having engaged in manufacturing violations, the battle lines have been drawn between the new and old managements of the company.

Shares of the company opened on a weak note and further tanked 9.3 per cent to Rs 391 on the BSE. At NSE, the stock tumbled 9.37 per cent to Rs 390.65.

Drug maker Ranbaxy's Japanese promoters on Wednesday blamed the company's former Indian owners for concealing and misrepresenting critical information about US investigation into sale of adulterated drugs, and said it will pursue legal remedies.

In the largest settlement by a generic medicine maker till date, its US subsidiary has pleaded guilty to felony charges relating to the manufacture and distribution of adulterated drugs made at two of drugmaker's manufacturing facilities in India.